Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Goodsaid

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Pharmacogenomics Journal|October 29, 2025
Genomic biomarkers of liver toxicity risk from UK Biobank dataAnna Shteto, Jawad Boulahfa, Adrien Etcheto, et al.
Nature Reviews. Genetics|October 1, 2008
The next steps for genomic medicine: challenges and opportunities for the developing worldBillie-Jo Hardy, Béatrice Séguin, Federico Goodsaid, et al.
Environmental and Molecular Mutagenesis|April 6, 2004
Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical moleculesRonald D Snyder, Greg S Pearl, George Mandakas, et al.
Drug Discovery Today. Technologies|July 2, 2014
An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path InitiativeWeida Tong, Stephen C Harris, Hong Fang, et al.
Toxicology Mechanisms and Methods|December 22, 2009
Gaining Confidence on Molecular Classification through Consensus Modeling and ValidationWeida Tong, Hong Fang, Qian Xie, et al.
Expert Review of Molecular Diagnostics|November 5, 2004
QA/QC: challenges and pitfalls facing the microarray community and regulatory agenciesLeming Shi, Weida Tong, Federico Goodsaid, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 23, 2020
A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical studyHarald Hampel, Coralie Williams, Adrien Etcheto, et al.
Orphanet Journal of Rare Diseases|March 12, 2015
Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpointsEmil D Kakkis, Mary O'Donovan, Gerald Cox, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 24, 2004
Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cellsDiana L Brassard, Marc M Delorenzo, Stuart Cox, et al.
Pharmacogenomics|December 5, 2009
Development of an undergraduate pharmacogenomics curriculumTravis J O'Brien, Federico Goodsaid, Margaret Plack, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Pharmacogenomics Journal|October 29, 2025
Genomic biomarkers of liver toxicity risk from UK Biobank dataAnna Shteto, Jawad Boulahfa, Adrien Etcheto, et al.
Nature Reviews. Genetics|October 1, 2008
The next steps for genomic medicine: challenges and opportunities for the developing worldBillie-Jo Hardy, Béatrice Séguin, Federico Goodsaid, et al.
Environmental and Molecular Mutagenesis|April 6, 2004
Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical moleculesRonald D Snyder, Greg S Pearl, George Mandakas, et al.
Drug Discovery Today. Technologies|July 2, 2014
An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path InitiativeWeida Tong, Stephen C Harris, Hong Fang, et al.
Toxicology Mechanisms and Methods|December 22, 2009
Gaining Confidence on Molecular Classification through Consensus Modeling and ValidationWeida Tong, Hong Fang, Qian Xie, et al.
Expert Review of Molecular Diagnostics|November 5, 2004
QA/QC: challenges and pitfalls facing the microarray community and regulatory agenciesLeming Shi, Weida Tong, Federico Goodsaid, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 23, 2020
A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical studyHarald Hampel, Coralie Williams, Adrien Etcheto, et al.
Orphanet Journal of Rare Diseases|March 12, 2015
Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpointsEmil D Kakkis, Mary O'Donovan, Gerald Cox, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 24, 2004
Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cellsDiana L Brassard, Marc M Delorenzo, Stuart Cox, et al.
Pharmacogenomics|December 5, 2009
Development of an undergraduate pharmacogenomics curriculumTravis J O'Brien, Federico Goodsaid, Margaret Plack, et al.
Pageof 3